Custo mensal de medicações anti-glaucomatosas no Brasil

Custo mensal de medicações anti-glaucomatosas no Brasil

Autores:

José Maria do Amaral Filho,
Rogério Antonio Reisig Moreira,
Leopoldo Magacho dos Santos Silva,
José Paulo Vasconcelos,
Eduardo Melani Rocha,
Vital Paulino Costa,
Newton Kara-José

ARTIGO ORIGINAL

Arquivos Brasileiros de Oftalmologia

versão impressa ISSN 0004-2749versão On-line ISSN 1678-2925

Arq. Bras. Oftalmol. vol.62 no.2 São Paulo abr. 1999

http://dx.doi.org/10.5935/0004-2749.19990028

SUMMARY

Purpose:

To evaluate the monthly cost of antiglaucomatous drugs available in Brazil.

Material and Methods:

Twenty antiglaucomatous drug preparations were obtainedfrom the local manufacturers or were bought at a local drugstore. Five bottles of each preparation were used. Five drops of each bottle were dispensed and their volumes measured by the same examiner using a micropipette. The mean drop volume was calculated. Based on these data, on the volume of the bottles and on their prices, the authors calculated: days of therapy per bottle, cost of one drop, drops per bottle and monthly drug cost. The only tablet presentation (Diamox(tm)) had its costs calculated based on the number of tablets per box.

Results:

Among the betablockers, the Betoptic S^mpreparation was the most expensive (R$ 9.78/eye/month), where as Timolol(tm) 0.25%c, Timoptol(tm) 0.25%c and 0.50%o were the less expensive (R$ 2.10/eye/month). Among the new drugs, Alphagan(tm), lopidine(tm) and Trusopt(tm) had costs between R$ 13.02 and R$ 15.60/eye/month when used b.i.d. and between R$ 19.53 and R$ 23.40/eye when used t.i.d. The Xalatan(tm) preparation had a monthly cost of R$ 20.60/eye.

Conclusions:

Drug costs may be influenced by factors other than the net bottle costs, such as posology, drop size and bottle volume. Some drug associations were found to be expensive when compared to the minimal national salary.

Keywords: Monthly cost; Drugs; Glaucoma; Therapy

REFERÊNCIAS

1 Wilensky JT. The role of Brimonidine in the treatment of Open-Angle Glaucoma Surv Ophthalmol 1996;41(S1):S3-S7.
2 Brubaker RF. Delayed Functional Loss in Glaucoma LII Edward Jackson Memorial Lecture [Letter]. Am J Ophthalmol 1996;121:473-83.
3 Costa VP, Vasconcellos JP, Pelegrino M, Kara-José N. O que os pacientes sabem sobre Glaucoma? Arq Brasil Oftalmol 1995;58:36-41.
4 Costa VP, Vasconcellos JP, Pelegrino M, Kara-José N. Análise da técnica de instilação de colírios em pacientes glaucomatosos. Rev Bras Oftalmol 1995;54:523-8.
5 Yasuoka ER, Mello PAA. Quem segue corretamente o tratamento clínico do Glaucoma? Arq Bras Oftalmol 1996;59:325-8.
6 Granstrom P. Glaucoma patients not compliant with theirdrug therapy: clinical and behavioural aspects. Br J Ophthalmol 1982;66:464-70.
7 Stewart WC et al. Daily Cost of B-adrenergic Blocker Therapy. Arch Ophthalmol 1997;115:853-6.
Política de Privacidade © Copyright, Todos os direitos reservados.